Maynard Um
-
-
-
-
-
-
-
NASDAQ: NRIX Nurix outlines 2026 goals for BTK degrader bexobrutideg
-
-
-
-
-
-
-
Nurix presents clinical data showing NX-1607 activates immune system
-
-
-
-
-
-
-
Nurix (NRIX) PT Lowered to $33 at Stifel
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Nurix (NRIX)
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Nurix (NRIX)
-
-
-
-
-
-
-
Nurix (NRIX) PT Lowered to $30 at Stephens
-
-
-
-
-
-
-
Nurix Therapeutics (NRIX) Appoints Roy D. Baynes to its Board
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

